There is already sufficient evidence to suggest that treg plays an important promoting role in the pathogenesis of HCC patients with viral hepatitis, especially CD4 + CD25 + Tregs, and immune checkpoint inhibitors (ICIs) targeting these immune cells can have therapeutic effects on HCC21. This evidence concerns the gene CD4 and hepatocellular carcinoma.